Akorn, Inc.

Animal pharma leader Akorn, Inc. had been in bankruptcy danger for several years. When a stern warning from the FDA and a failed takeover bid derailed their business, they were left with nowhere else to turn.

In late 2018, Germany based healthcare group Fresenius SE & Co KGaA backed out of its $4.3 billion offer for Akorn, Inc. At that time, Fresenius discovered issues with Akorn’s pharmaceutical production, quality control and drug testing, including the discovery of anesthetics tainted with metal shavings. Later on in 2019, the U.S. Food and Drug Administration (FDA) issued warning letters to Akorn relating to two of its plants—one in Somerset, N.J. and the other in Decatur, Ill.— also after finding manufacturing violations. Regulators found that the manufacturing miscues “pose[d] a risk to the public.”

Amidst the turmoil, Akorn Inc.'s FRISK® score was fixed at a "1," with the company's market cap falling from $4 billion USD in 2017 to $28 million in the aftermath of the Fresenius deal collapsing.

Akorn, Inc. FRISK® score
Ready to learn more?

Our FRISK® score model incorporates four powerful risk inputs:

  • “Merton”-type model of stock market capitalization and volatility
  • Financial ratios, including those used in the Altman Z”-Score Model
  • Bond agency ratings from Fitch, Moody's, and DBRS Morningstar
  • Website click pattern data from CreditRiskMonitor® subscribers, representing key credit decision-makers at more than 35% of current Fortune 1000 companies plus thousands of other large companies worldwide

Since the start of 2017, the FRISK® score’s rate of success in capturing public company bankruptcy is 96%. In any given year, you can count on one hand the times we miss – and in those outlier cases, the circumstances deal with unusual, unforeseen events such as natural disasters and CEO fraud.

Download the free report to learn more.

About Bankruptcy Case Studies

CreditRiskMonitor® Bankruptcy Case Studies provide post-filing analyses of public company bankruptcies. Our case studies educate subscribers about methods they can apply to assess bankruptcy risk using our proprietary FRISK® score, robust financial database, and timely news alerts.

In nearly every case, a low FRISK® score gave our subscribers early warning of financial distress within a one-year time horizon. Our proprietary FRISK® score predicts bankruptcy risk at public companies with 96% accuracy. The score is formulated by a number of indicators including stock market capitalization and volatility, financial ratios, bond agency ratings from Moody’s, Fitch and DBRS, and crowdsourced behavioral data from a subscriber group that includes 35% of the Fortune 1000 and thousands more worldwide.

Whether you are new to credit analysis or have decades of experience under your belt, CreditRiskMonitor® Bankruptcy Case Studies offer unique insights into the business and financial decline that precedes bankruptcy.